In This Article:
Release Date: May 12, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Quanterix Corp (NASDAQ:QTRX) exceeded expectations in Q1 2025, showcasing resilience in its instruments and consumables business.
-
The company reported its highest consumables quarter, with consumables revenue up 6% year-over-year.
-
Quanterix Corp (NASDAQ:QTRX) is committed to achieving positive cash flow by 2026, supported by a strong balance sheet.
-
The pending merger with EOA Biosciences is expected to enhance Quanterix Corp (NASDAQ:QTRX)'s market position, with significant synergies anticipated.
-
The launch of Samoa One platform is on track, promising to deliver up to 10x the sensitivity of existing systems, which could set a new standard in the field.
Negative Points
-
Total revenue for Q1 2025 decreased by 5% compared to the prior year, indicating some challenges in revenue growth.
-
Accelerator lab revenue declined by 36%, primarily due to a decrease in large multi-million dollar projects from pharma customers.
-
The company revised its full-year 2025 revenue guidance downwards, citing pressures from academic funding and biopharma spending.
-
There is a noted pressure on instrument sales, with expectations for them to remain flat compared to 2024.
-
The market environment is challenging, with concerns around academic funding, biopharma spending, and tariffs impacting the company's outlook.
Q & A Highlights
Q: Can you provide insights into the performance of the accelerator and consumables segments this quarter, and how do you foresee their growth for the rest of the year? A: (Masoud Talu, CEO) The consumables segment had a record quarter, driven by strong demand in neurology and emerging interest in inflammation and cytokine-based assays. For the accelerator, Q1 aligned with expectations, but the pipeline is taking longer to develop. While recurring revenue is strong, large projects are slower to materialize, impacting growth projections. (Vandana Shriram, CFO)
Q: How will the Samoa One platform's compatibility with existing flow cytometers impact your market strategy, particularly in immunology and oncology? A: (Masoud Talu, CEO) The compatibility with flow cytometers allows us to leverage a broad installed base, accelerating menu development and expanding into immunology and oncology. This strategy meets customers' needs in a capital-constrained environment and enhances synergies with the EOA Biosciences acquisition.
Q: What are the expectations for the Lucent AD pricing and its impact on revenue? A: (Masoud Talu, CEO) We anticipate multi-marker pricing in the high triple digits, with reimbursement expected to begin in early 2026. This pricing strategy reflects the test's comprehensive nature and market differentiation.